DX 619

Known as: DX-619, DX619 compound 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2012
02420052012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
OBJECTIVES The aim of the study was to test in vitro activities of the novel des-F(6)-quinolone DX-619 against methicillin… (More)
Is this relevant?
2006
2006
Interactions of DX-619, a novel fluoroquinolone antibacterial, and levofloxacin (LVFX) with the human renal organic cation… (More)
Is this relevant?
2006
2006
The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical… (More)
Is this relevant?
2006
2006
The in vitro activity of DX-619, a new des-F(6) quinolone, against anaerobic bacteria was evaluated. DX-619 showed potent… (More)
Is this relevant?
2006
2006
DX-619 is a novel des-fluoro(6) quinolone with potent activity against gram-positive pathogens. The in vivo activity of DX-619… (More)
Is this relevant?
2006
2006
In this study, the potency of DX-619, a novel des-fluoro(6)-quinolone agent, was compared with that of vancomycin (VCM) in a… (More)
Is this relevant?
2005
2005
The in vitro activities of DX-619, des-fluoro(6) quinolone, against 1,208 clinical isolates were examined. DX-619 was… (More)
  • table 1
  • table 2
Is this relevant?
2005
2005
The in vitro activity of DX-619, a new des-F(6)-quinolone, was tested against staphylococci and compared to those of other… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2005
2005
The in vitro postantibiotic effects (PAEs), the postantibiotic sub-MIC effects (PA-SMEs), and the sub-MIC effects (SMEs) of DX… (More)
  • figure 1
  • table 1
Is this relevant?
2005
2005
DX-619, a novel des-fluoro(6) quinolone, was 16- to 32-fold, twofold, and four- to eightfold more potent than ciprofloxacin… (More)
Is this relevant?